CLH Stock Barely Moves Since Reporting Q2 Earnings Beat: Here's Why
The stock price has not witnessed any significant impact of the earnings beat since the company released results on July 30.
CLH's earnings of $2.36 per share outpaced the Zacks Consensus Estimate by 1.3% but decreased 4.1% from the year-ago quarter. Total revenues of $1.5 billion missed the consensus estimate by 2% and decreased marginally on a year-over-year basis.
The stock has gained 5.1% in the year-to-date period compared with the 10.8% rise of the industry it belongs to and the 7.3% growth of the Zacks S&P 500 composite.
Clean Harbors, Inc. Price, Consensus and EPS Surprise
Clean Harbors, Inc. price-consensus-eps-surprise-chart | Clean Harbors, Inc. Quote
CLH's Segmental Revenues
Environmental Services (ES) revenues of $1.3 billion increased 2.5% from the year-ago quarter, meeting our estimate figure. Continued strength from the HEPACO buyout and growth in pricing, and higher incineration utilization drove this segment's revenues.
Revenues from Safety-Kleen Sustainability Solutions (SKSS) totaled $219.7 million, a 13.9% year-over-year decline and below our forecast of $259.5 million. Lower base oil prices, led by weak demand, caused this decline.
Clean Harbors' Profitability Performance
Adjusted EBITDA of $336.2 million grew 2.6% from the year-ago quarter and beat our estimation of $331.4 million. The adjusted EBITDA margin was 21.7%, up 60 basis points from the year-ago quarter.
Segment-wise, adjusted EBITDA for ES amounted to $376.2 million, increasing 4.5% year over year. The figure missed our estimate of $379.2 million. Adjusted EBITDA for SKSS was $38.3 million, down 25.6% from the year-ago quarter and missing our estimate of $42.2 million.
Balance Sheet & Cash Flow of CLH
Clean Harbors exited the quarter with cash and cash equivalents of $600.2 million compared with $489.4 million at the end of the preceding quarter. Inventories and supplies were $383.4 million compared with $376 million in the first quarter of 2025.
Long-term debt (less current portion) was $2.8 billion, flat with the previous quarter.CLH generated $208 million in net cash from operating activities. The capital expenditure amounted to $90 million. The adjusted free cash flow utilized was $133.2 million.
Clean Harbor's 2025 Guidance
For 2025, CLH's guidance for adjusted EBITDA is updated to $1.16-$1.20 billion from the preceding quarter's view of $1.15-$1.21 billion. The adjusted free cash flow is expected to be $430-$490 million.
Clean Harbor currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Earnings Snapshot
The Interpublic Group of Companies, Inc. IPG reported impressive second-quarter 2025 results.
IPG's adjusted earnings of 75 cents per share surpassed the Zacks Consensus Estimate by 36.4% and jumped 23% from the year-ago quarter. Revenues before billable expenses (net revenues) of $2.2 billion beat the consensus estimate by a slight margin but declined 19.8% year over year. Total revenues of $2.5 billion decreased 7.2% year over year and outpaced the Zacks Consensus Estimate of $2.2 billion.
TransUnion TRU reported impressive second-quarter 2025 results.
TRU's quarterly adjusted earnings (adjusting 52 cents from non-recurring items) of $1.08 per share surpassed the consensus mark by 9.1% and increased at the same rate year over year. Total revenues of $1.1 billion outpaced the consensus mark by 3.7% and rose 9.5% from the year-ago quarter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Interpublic Group of Companies, Inc. (The) (IPG) : Free Stock Analysis Report
Clean Harbors, Inc. (CLH) : Free Stock Analysis Report
TransUnion (TRU) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
CareTrust REIT (CTRE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2025, CareTrust REIT (CTRE) reported revenue of $112.47 million, up 63.3% over the same period last year. EPS came in at $0.43, compared to $0.07 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $107.52 million, representing a surprise of +4.6%. The company delivered an EPS surprise of -4.44%, with the consensus EPS estimate being $0.45. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how CareTrust REIT performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Rental income: $86.03 million versus $75.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +55.3% change. Revenues- Interest income from other real estate related investments and other income: $23.55 million versus $25.05 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +74.7% change. Net Earnings Per Share (Diluted): $0.35 compared to the $0.36 average estimate based on two analysts. View all Key Company Metrics for CareTrust REIT here>>> Shares of CareTrust REIT have returned +6% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CareTrust REIT, Inc. (CTRE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say
Sarepta Therapeutics (SRPT) reported $611.09 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 68.4%. EPS of $2.02 for the same period compares to $0.07 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $529.54 million, representing a surprise of +15.4%. The company delivered an EPS surprise of +81.98%, with the consensus EPS estimate being $1.11. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product, net: $513.12 million versus $506.99 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +42.3% change. Revenues- PMO Products: $231.27 million versus the seven-analyst average estimate of $228.28 million. Revenues- Collaboration: $97.97 million compared to the $21.79 million average estimate based on seven analysts. The reported number represents a change of +4011.1% year over year. Revenues- Product, net- ELEVIDYS: $281.85 million versus the seven-analyst average estimate of $277.86 million. The reported number represents a year-over-year change of +131.6%. View all Key Company Metrics for Sarepta Therapeutics here>>> Shares of Sarepta Therapeutics have returned -12% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Upturn
2 hours ago
- Business Upturn
Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) — Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025. Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability of its IMPACT Phase 2b MASH Trial According to the complaint, during the class period, defendants repeatedly touted their positive expectations of the topline results of the Company's MASH trial. On June 26, 2025, Altimmune announced the results from its IMPACT Phase 2b MASH trial of Pemvidutide in the treatment of MASH. Specifically, the Company failed to achieve statistical significance in the trial due to a higher-than-expected placebo response. On this news, the price of Altimmune's common stock fell from $7.71 per share on June 25, 2025 to $3.61 per share on June 26, 25, or more than 53% in a single day. What Now: You may be eligible to participate in the class action against Altimmune, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their papers with the court by October 6, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Altimmune, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
